Dipeptidyl peptidase (DPP-4) inhibitors increase incretin hormone levels, which improve insulin secretion, insulin resistance and reduce glucagon levels34,35, and they have been proven to be effective and safe in patients with T2D36–38. Here, GCG is linked to Insulin resistance.